ArticleBMJ open2026

Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU).

François Dépret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.